Dose Escalation Study of Concomitant BIBF 1120 + BIBW 2992 in Patients With Advanced Solid Tumours.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The primary endpoint of this trial is the assessment of the incidence of Dose Limiting Toxicity (DLT) in the combination BIBW 2992 and BIBF 1120 when administered concomitantly and this incidence will be used to determine the Maximum Tolerated Dose (MTD)
28-day
Yes
Boehringer Ingelheim
Study Chair
Boehringer Ingelheim Pharmaceuticals
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
1239.14
NCT00998296
October 2009
October 2014
Name | Location |
---|